Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Senhwa Biosciences's OCF Margin % or its related term are showing as below:
ROCO:6492'
s OCF Margin % Range Over the Past 10 Years
Min: -172317.19 Med: -44194.49 Max: -23220.28
Current: -23220.28
During the past 13 years, the highest OCF Margin % of Senhwa Biosciences was -23220.28%. The lowest was -172317.19%. And the median was -44194.49%.
ROCO:6492's OCF Margin % is ranked worse than 95.89% of 950
companies
in the Biotechnology industry
Industry Median: -64.565
vs ROCO:6492: -23220.28
Senhwa Biosciences OCF Margin % Related Terms
Senhwa Biosciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Senhwa Biosciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6492 vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Senhwa Biosciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senhwa Biosciences OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Senhwa Biosciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senhwa Biosciences (ROCO:6492) has a OCF Margin % of -22,689.17% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Senhwa Biosciences and its competitors. According to the industry distribution chart, Senhwa Biosciences ranks #911 out of 950 companies in the Biotechnology industry, placing it in the top 95.9%.
Is Senhwa Biosciences' OCF Margin % too high?
Senhwa Biosciences' current OCF Margin % is -22,689.17%. Based on the distribution chart, Senhwa Biosciences ranks #911 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senhwa Biosciences has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Senhwa Biosciences' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Senhwa Biosciences ranks #911 out of 950 companies for OCF Margin %. This places Senhwa Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Senhwa Biosciences and its competitors. Senhwa Biosciences's current OCF Margin % is -22,689.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senhwa Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Senhwa Biosciences (ROCO:6492) is currently considered Fairly Valued. The stock's GF Value™ is NT$46.74, compared to a current price of NT$43.70 — trading 6.5% below its estimated fair value. The current OCF Margin % is -22,689.17%. Senhwa Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Senhwa Biosciences (ROCO:6492), the current OCF Margin % is -22,689.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?
Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued.
The current stock price of NT$43.70 is trading 6.5% below its estimated GF Value™ of NT$46.74.
GuruFocus considers Senhwa Biosciences to be Fairly Valued.
Key valuation signals for ROCO:6492:
OCF Margin %: -22,689.17%
GF Value™: NT$46.74 vs. price of NT$43.70 (6.5% below fair value)
No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score
Get the complete analysis for ROCO:6492
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6492 has been successfully added to your 
